Key result
Two years after bOPV campaigns in Papua New Guinea, the seroprevalence of neutralizing polio antibodies for serotype 1 remained high at 98.3% (95% CI: 97.4-98.9) among children.
Why the study?
Following an outbreak response to type 1 circulating vaccine-derived poliovirus in Papua New Guinea involving eight vaccination rounds, the prevalence of neutralizing polio antibodies in children was assessed two years later.
Cross-Sectional (n=984)
Yes
High seroprevalence of neutralizing polio antibodies was maintained two years after the cVDPV1 outbreak response in Papua New Guinea, demonstrating the effectiveness of the vaccination campaigns.
Answers are grounded in this paper and cite their sources.
Supports durable type 1/3 immunity two years post-cVDPV1 campaign; leaves open serotype 2 protection gaps in similar settings.
Background: In June 2018, a type 1 circulating vaccine-derived poliovirus (cVDPV1) outbreak was declared in Papua New Guinea (PNG), resulting in a total of 26 paralytic confirmed cases. Eight vaccination campaign rounds with bivalent oral poliovirus vaccine (bOPV) were carried out in response. Prevalence of neutralizing polio antibodies in children was assessed two years after the outbreak response was completed. Methods: We conducted a cross-sectional serological survey among children aged 6 months-10 years selected from six provinces in PNG to evaluate seroprevalence of neutralizing polio antibodies to the three poliovirus serotypes and analyse sociodemographic risk factors. Findings: We included 984 of 1006 enrolled children in the final analysis. The seroprevalence of neutralizing polio antibodies for serotype 1, 2 and 3 was 98.3% (95% CI: 97.4-98.9), 63.1% (95% CI: 60.1-66.1) and 95.0% (95% CI: 93.6-96.3), respectively. Children <1 year had significantly lower type 1 seroprevalence compared to older children (p < 0.001); there were no significant differences in seroprevalence among provinces. Interpretation: PNG successfully interrupted transmission of cVDPV1 with several high coverage bOPV campaigns and seroprevalence remained high after two years. The emergence of cVDPV strains underscores the importance of maintaining high levels of routine immunization coverage and effective surveillance systems for early detection.
No takes yet. Share an insight, caveat, or question.
Pomat et al. (2023) conducted a cross-sectional in cVDPV1 outbreak (n=984). bivalent oral poliovirus vaccine (bOPV) campaigns was evaluated on seroprevalence of neutralizing polio antibodies for serotype 1 (95% CI 97.4-98.9). Two years after bOPV campaigns in Papua New Guinea, the seroprevalence of neutralizing polio antibodies for serotype 1 remained high at 98.3% (95% CI: 97.4-98.9) among children.
Synapse has enriched 10 related papers. Consider them for comparative context: